Orexigen Therapeutics is a

public In public relations and communication science, publics are groups of individual people, and the public (a.k.a. the general public) is the totality of such groupings. This is a different concept to the sociological concept of the ''Öffentlichkei ...

American

pharmaceutical company The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate sympto ...

focused on development of treatments for

obesity Obesity is a medical condition, sometimes considered a disease, in which excess body fat has accumulated to such an extent that it may negatively affect health. People are classified as obese when their body mass index (BMI)—a person's we ...

. The company is based in

La Jolla, California La Jolla ( , ) is a hilly, seaside neighborhood within the city of San Diego, California, United States, occupying of curving coastline along the Pacific Ocean. The population reported in the 2010 census was 46,781. La Jolla is surrounded on ...

and was established by Eckard Weber in 2002. As a public company, Orexigen is

traded Trade involves the transfer of goods and services from one person or entity to another, often in exchange for money. Economists refer to a system or network that allows trade as a market. An early form of trade, barter, saw the direct excha ...

on the

NASDAQ The Nasdaq Stock Market () (National Association of Securities Dealers Automated Quotations Stock Market) is an American stock exchange based in New York City. It is the most active stock trading venue in the US by volume, and ranked second ...

exchange under the stock symbol OREX. The company has a single product, Contrave, approved for use in the United States in 2014. Contrave was designed not only to curb hunger but also reduce cravings. Observation of the market performance of

Qsymia Phentermine/topiramate, sold under the brand name Qsymia, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is r ...

and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering. Orexigen declared bankruptcy in 2018 and was sold to Nalpropion.

References

Health care companies based in California Pharmaceutical companies established in 2002 Pharmaceutical companies of the United States Companies listed on the Nasdaq 2002 establishments in California {{US-manufacturing-company-stub